Djundeva, Jasmina
Preferred name
Djundeva, Jasmina
Official Name
Djundeva, Jasmina
Translated Name
Џундева, Јасмина
Alternative Name
Jasmina Djundeva
Jasmina Dzundeva
Dzundeva, Jasmina
Djundeva. Jasmina
Dzundeva, J
Djundeva, J
Јасмина Џундева
Main Affiliation
Email
jasmina.djundeva@medf.ukim.edu.mk
3 results
Now showing 1 - 3 of 3
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, INTRAVAGINAL BRACHYTHERAPY SUPPORTED BY LOCAL ANAESTHESIA IN THE TREATMENT OF ENDOMETRIAL CANCER – SINGLE INSTITUTIONAL EXPERIENCE(Department of Anaesthesia and Reanimation, Faculty of Medicine, “Ss. Cyril and Methodius” University Skopje, R.N.Macedonia, 2020-10); ; ; ; Bojoski PIntravaginal brachytherapy in endometrial cancer is an inevitable part of the treatment. In the early stages of the disease, it signifcantly reduces the risk of local recurrence in the vaginal cuff with low rates of late toxicity. In the advanced stages, it provides palliative control usually with a hemostyptic effect. Brachytherapy may be the only postoperative treatment – monotherapy, or as a boost following the external beam radiotherapy, depending on many prognostic factors. Placing the vaginal applicator deep into the vagina is certainly an uncomfortable feeling, combined with pain, anxiety and discomfort. Local anaesthesia helps in reducing the painful sensations, gives adequate relaxation, but more importantly provides a quality insight into the condition of the vagina, and thus a successful application. Through our experience with the local vaginal anaesthesia with lidocaine 2% gel, we want to emphasize that intravaginal brachytherapy, supported by local anaesthesia, regardless of the degree of pain relief is directly related to successful treatment. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, CURRENT EVIDENCE OF TREATMENT WITH TUMOR TREATING FIELDS (TTF) IN PATIENTS WITH GLIOBLASTOMA AS A FOURTH MODALITY TREATMENT OPTION(Department of Anaesthesia and Reanimation, Faculty of Medicine, “Ss. Cyril and Methodius” University Skopje, R.N.Macedonia, 2022-12); ; Petkovska GordanaBackground: High-grade glial tumors (HGGTs) are the most common malignant tumors that occur in the central nervous system; they form about 40% of all primary brain tumors. The group of high-grade glial tumors includes: Anaplastic astrocytoma (AA), Anaplastic Oligodendroglioma (AO) as well as Glioblastoma (GBM). Tumor Treating Fields (TTFs) itself is a completely non-invasive and innovative approach, and because of the specific frequency which it uses, it has a selective anticancer or antimitotic effect on malignant cells. Methods: A systematic search was conducted in PubMed in database and the most relevant articles were selected which are forming scientific evidence for application of this type of treatment in clinical setting. Results: In the absence of meta-analysis, the most relevant articles were selected and a combination of evidence has been extracted to systematically organize this article. Positive studies with clinical benefits have been selected for further analysis. Conclusion: As a result of several clinical and preclinical researches, the inclusion of the TTF (Tumor Treating Fields) treatment modality to the earlier traditional three modality treatment for patients with glioblastoma multiforme, is considered to become a standardized treatment, i.e., according to the novel approach, four modalities are used for newly diagnosed or recurrent patients with GBM modality treatment, i.e., cocktail-based therapy. And it’s considered a valuable option for this type of solid tumors, so-called “cold” tumors. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, SINGLE INSTITUTION EXPERIENCE OF TWO-DIMENSIONAL VERSUS TRI-DIMENSIONAL INTRACAVITARY BRACHYTHERAPY IN LOCALLY ADVANCED CERVICAL CARCINOMA(University of Nis, Faculty of Electronic Engineering, 2016-05-23); ; ; ; Nadica DimitrovskaIntroduction Cervical carcinoma is the third most present malignancy at women worldwide. Beside the screening program for early cancer detection, locally advanced disease is still present, thus requiring specific therapeutic approach. Intracavitary high dose rate (HDR) brachytherapy is one of the most efficient radiotherapy techniques in cervical cancer treatment which builds up upon the external beam radiation (EBRT) dose. Limited two-dimensional (2D) planning in ICRU points is moreover replaced by more sophisticated tridimensional (3D) volumetric planning. Materials and methods 22 patients with diagnosed inoperable locally advanced cervical carcinoma were treated in 5 month period. Median age was 51 years, planocellular carcinoma was dominant histological type with 81% (18) and according to the clinical stage of disease 77% (17 ) were in IIB stage. EBRT chemo-radiation was applied to all patients, followed by 3D HDR intracavitary brachytherapy given in 3 applications (one/weekly), with prescribed dose of 7Gy to point A. Brachytherapy planning was made in 2D and 3D setting for dosimetric comparison purpose. 2D planning utilized 2D radiography with C-arm or 2D simulator, while 3D used CT scans. For 2D plans there were used ICRU 38 defined reference points, while 3D plans were calculated upon delineated volumes of interest and organs of risk. Doses were calculated and reported according to ICRU 38. Brachytherapy itself was performed on GammaМed Plus apparatus, using Ir-192 source. Total treatment time was evaluated which encompassed the period from the first external beam fraction till the last brachytherapy application. Results 2D vs 3D dosimetric comparison showed no significant difference in point A (2D) vs reconstructed point A (3D). However, 3D planning showed the isodose coverage of the whole target volume with average value of 56.9% covered with 100%, while 63.3% received 90% of the prescribed dose. Generally organs of risk (OR) in 2D planning had significantly lower ICRU dose values compared to 3D planning where maximal dose points and absorbed dose in volume of 2ccm were higher than ICRU points. Volumetric doses showed more realistic view of isodose projection in surrounding tissues and organs, thus reducing the adverse events rate and potential later complications such as fistulae and strictures. However, OR related results were not the main aim of this study. Total Treatment time averaged 69 days (57 to 89) showing a 23.2% deviation (extending) of the treatment optimum of 56 days. 12 (55%) patients finished their treatment in 57-70 days range, 7 (31%) in 71-80 days, while 3 (14%) finished in timeframe of 81-89 days. Conclusion 3D planning offers the option for treatment individualization and volumetric dose presentation which results in better local disease control and surrounding tissues preservation. In our clinic 2D planning was a decades-long tradition, but now planning is being shifted towards the 3D approach.